Summary of "Pharmacology - Pharmakodynamics E02 | L4 | FMGE Dec'21 | Let's crack NEET PG | Dr. Priyanka Sachdev"

Summary of the YouTube Video: "Pharmacology - Pharmakodynamics E02 | L4 | FMGE Dec'21 | Let's crack NEET PG | Dr. Priyanka Sachdev"

Main Topics Covered:

  1. Introduction to Pharmacodynamics
    • Continuation from previous lecture on dose-response curves.
    • Focus on the mechanism of drug action.
    • Explanation of what Pharmacodynamics means: "What the drug does to the body."
    • Differentiation from pharmacokinetics ("What the body does to the drug").
  2. Mechanism of Drug Action
    • Drugs act by binding to receptors located on the cell surface or inside cells.
    • Receptors can be proteins on the membrane, enzymes, ion channels, or intracellular nuclear receptors.
    • Drug-receptor binding triggers intracellular signaling via transducer proteins.
  3. Receptors and Transducer Proteins
    • Receptors are specific proteins that drugs bind to initiate effects.
    • Transducer proteins in the cytoplasm carry the signal from the receptor to the nucleus.
    • Activation of nuclear genes leads to protein synthesis which mediates drug effects.
    • Examples of receptor types: alpha and beta adrenergic receptors, muscarinic receptors (M1, M2, M3), nicotinic receptors, histaminic receptors (H1, H2, H3, H4), serotonin receptors (5-HT1, 5-HT2, etc.).
  4. Types of Transduction Mechanisms (Five Main Types)
    • G Protein-Coupled Receptors (GPCRs): 7 transmembrane helices, with alpha, beta, gamma subunits.
      • Alpha subunit binds GTP (active) or GDP (inactive).
      • Activation leads to effects like activation of Adenylate Cyclase, production of cAMP, or phospholipase C activation.
    • Ion Channel-Linked Receptors
    • Transmembrane Enzyme-Linked Receptors (e.g., Tyrosine Kinase)
    • Intracellular Receptors (Nuclear Receptors)
    • Others (not detailed here)
  5. Detailed Explanation of GPCR Mechanism
    • Drug binds receptor → GDP replaced by GTP on alpha subunit → alpha subunit dissociates → activates enzymes like Adenylate Cyclase → converts ATP to cAMP → cAMP activates protein kinases → protein kinases modulate cellular functions and gene expression.
    • Example: Adrenaline binding to beta-adrenergic receptor activating Adenylate Cyclase.
    • Another pathway: Phospholipase C activation leading to IP3 and DAG production → IP3 mobilizes intracellular calcium → activates protein kinase C.
  6. Intracellular (Nuclear) Receptors
    • These receptors are inside the cytoplasm or nucleus.
    • Drugs must be lipid-soluble to enter the cell and bind these receptors.
    • Upon binding, receptor undergoes conformational change, dimerizes, translocates to nucleus, binds DNA, and modulates gene transcription.
    • Examples: Steroid hormones, thyroid hormone, retinoic acid.
  7. Examples of Receptors and Their Pathways
    • Alpha-1 adrenergic receptor → IP3/DAG pathway.
    • Beta-2 adrenergic receptor → Adenylate Cyclase/cAMP pathway.
    • Histamine H1 → IP3/DAG.
    • Histamine H2 → Adenylate Cyclase/cAMP.
    • Muscarinic M1, M3 → IP3/DAG.
    • Muscarinic M2 → Adenylate Cyclase inhibition.
  8. Toxicity and Adverse Drug Reactions (ADR)
    • Types of toxicity: acute, chronic, carcinogenic, neonatal, and investigative.
    • Acute toxicity: tested on animals for 4 weeks, multiple species, multiple doses.
    • Chronic toxicity: >6 months testing.
    • Carcinogenicity: 2-year studies.
    • ADR classification:
      • Type A (augmented, dose-dependent)
      • Type B (bizarre, unpredictable)
      • Type C (chronic)
      • Type D (delayed)
      • Type E (end of treatment)
      • Type F (failure of therapy)
    • Examples: Hydroxychloroquine causing retinopathy (chronic), withdrawal effects like alcohol withdrawal syndrome.
  9. Drugs During Pregnancy
    • FDA pregnancy categories: A, B, C, D, X.
    • Category A: Safe in human studies (e.g., Levothyroxine, folic acid).
    • Category B: Animal studies safe, no human data.
    • Category C: Animal studies show adverse effects, no human data.
    • Category D: Evidence of human fetal risk but benefits may warrant use.
    • Category X: Contraindicated in pregnancy (e.g., Methotrexate).

Category ?

Educational

Share this summary

Is the summary off?

If you think the summary is inaccurate, you can reprocess it with the latest model.

Summarize another video

Video